Research of Predictive Factors to Immune Thrombopenic Purpura

Summary

It is about a multicentric study prospective of more than patients' 60 years with a thrombopenia isolated of less than 100 G/L blood platelet without cause found to estimate so certain examinations realized in the diagnosis (medullary cytogenetics, dosage of the TPO, the Anti-platelet antibodies, isotopic lifetime of platelet) are in favour of the diagnosis of PTI.

Conditions

• Purpura Thrombopenic

Interventions

OTHER

Blood tests and bone marrow biopsy repeated

Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet. The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal.

Sponsors & Collaborators

• Assistance Publique Hopitaux De Marseille

  collaborator OTHER

• Henri Mondor University Hospital

  collaborator OTHER

• Hôpital Jean Verdier

  collaborator OTHER

• CH Abbeville

  collaborator UNKNOWN

• CH Compiègne

  collaborator UNKNOWN

• CHRU BREST

  collaborator UNKNOWN

• CHRU LILLE

  collaborator UNKNOWN

• University Hospital, Angers

  collaborator OTHER_GOV

• Centre Hospitalier Universitaire de Besancon

  collaborator OTHER

• CHU CAEN

  collaborator UNKNOWN

• CHU NICE

  collaborator UNKNOWN

• CHU Rennes

  collaborator UNKNOWN

• University Hospital, Toulouse

  collaborator OTHER

• GROUPE HOSPITALIER INSTITUT CATHOLIQUE

  collaborator UNKNOWN

• Centre Hospitalier Universitaire, Amiens

  lead OTHER

Principal Investigators

• Jean Pierre MD MAROLLEAU, phD · CHU AMIENS

• mathilde HUNAULT BERGER, Ph D · University Hospital, Angers

• NADINE MAGY BERTRAND, PH D · Centre Hospitalier Universitaire de Besancon

• Olivier FAIN, PH D · HOPITAL JEAN VERDIER, BONDY

• BRIGITTE PAN PETESCH, D · CHU BREST

• MICHEL LEPORRIER, PH D · University Hospital, Caen

• BERTRAND GODEAU, PH D · CHU CRETEIL

• PHILIPPE BIERLING, PH D · EFS IVRY SUR SEINE

• LOUIS TERRIOU, PH D · CHRU LILLE

• JEAN MARC DURAND, PH D · LA CONCEPTION MARSEILLE

Study Design

Allocation

NA

Purpose

DIAGNOSTIC

Model

SINGLE_GROUP

Eligibility

Min Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-01-15

Primary Completion

2022-12-28

Completion

2022-12-28

Countries

• France

Study Locations